Method to Remove Mycoplasma Contamination from Virus Stocks

Mycoplasma are a form of bacteria that are commonly found as contaminants in cell cultures. They adversely affect cell line growth rates and viral vaccine production. Mycoplasma contamination is a challenge for the vaccine industry and virology researchers. Current commercial reagents or kits only temporarily inhibit the growth of mycoplasma, but cannot eliminate the contaminants.

Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types

Streptococcus pneumoniae, or pneumococcus, is a type of bacteria that causes pneumococcal disease. Pneumococcal infections can range from ear and sinus infections to pneumonia and bloodstream infections. Children younger than 2 years old and adults 65 years or older are among those most at risk for disease.

Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development

Streptococcus pneumoniae (S. pneumonia), bacteria commonly referred to as pneumococcus, are a significant cause of disease resulting in 1.5 million deaths every year worldwide according to the World Health Organization. The major types of pneumococcal disease are pneumonia (lung infection), bacteremia (bloodstream infection), and meningitis (infection of the tissue covering of the brain and spinal cord). Less severe pneumococcal illnesses include ear and sinus infections.

The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays

CDC researchers have developed probes and primers for detecting the 2009 pandemic influenza A H1N1 virus in patient samples using real-time reverse transcription-polymerase chain reaction (rRT-PCR) methods. These primers and probes were originally developed in 2009 and were cleared by the FDA as part of a domestic human diagnostic testing panel in June 2010. These were also updated to increase specificity and/or sensitivity of the detection methods.

New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance

H7N9 influenza viruses are predominately avian (bird) pathogens, however, since 2013, they have infected more than 1500 humans with a mortality rate of nearly 40% in confirmed cases. H7N9 viruses continue to be a threat to public health. Treatment for people infected with H7N9-subtype influenza A (H7N9) commonly includes the use of drugs that inhibit neuraminidase, a protein found on the virus’ surface. However, like other influenza viruses, H7N9 can become resistant to these drugs.

Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin

Anthrax is a serious infectious disease caused by bacteria known as Bacillus anthracis. Anthrax-contaminated spores can be found naturally in soil and they commonly affect domestic and wild animals around the world. Although rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products.

Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection

Mycoplasma pneumoniae (M. pneumonia) can cause several different types of infection including chest colds and pneumonia. M. pneumoniae is a leading cause of community-acquired pneumonia. People of all ages are at risk for getting M. pneumonia infection, but it is most common among young adults and school-aged children. Current methods of detecting this agent are laborious and time consuming, so testing is not usually performed. However, knowing whether someone has M. pneumoniae infection is important for choosing the right antibiotic for treatment.